semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Moderate-to-severe Atopic Dermatitis AD according to the United Kingdom (UK) working party diagnostic Moderate to severe AD Objective > 20 or Currently anti-inflammatory systemic treatment for AD or Previous anti-inflammatory systemic treatment for AD within past 24 months
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 6.0-17.0,  Asthma Age 6-17 years old Admission to Children's Hospital Colorado with an asthma exacerbation between Jan 1 2017 and Dec 31 2017  Language other than English or Spanish (application for monitoring adherence is only available in these languages) Presence of other complex medical problems including Cystic Fibrosis Tracheostomy/ventilator dependence other severe chronic lung disease, and significant developmental delays Home schooled or not in school Following up with an allergy or pulmonary provider outside the CHCO system after hospital discharge
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Cleft Lip and Palate Subject with a NSCL/P or CL/P of unknown etiology national health care insurance holders  Subject with a CL/P of known etiology Subject with a NSCL/P and an IRF6 mutation
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 12.0-70.0,  Severe Asthma All Asthma Patients presenting at study clinics who are between 12 and 70 years and older resident within 30km of the enrolling sites  Asthma patients with contra-indications to any of the study procedures and tests. In addition the following patients will be excluded Patients with a primary diagnosis of an alternative lung disease (e.g.: COPD, or bronchiectasis, pulmonary fibrosis.) Patients with another significant disease likely to confound assessment of asthma (e.g: active tuberculosis) Patients unable to perform study tests and procedures Patients over 70 years of age, patients who have been exposed to experimental treatments within the past three months Pregnant women
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Severe Asthma Patients between 18 and 70 years of age Patients diagnosed with severe uncontrolled asthma Patients who give informed consent Previous treatment with omalizumab that was discontinued because lack of efficacy (symptoms -ACT <20, exacerbations) or adverse effects Patients with a high blood eosinophil count (400 μl) at least once in the previous 3 years Women should be surgically sterilized, at least 2 years have passed since menopause, or must have a negative pregnancy test within 7 days prior to initiation of treatment Women of childbearing potential (not surgically sterilized or menopausal for less than 2 years) should use a medically accepted method of contraception and should agree to continue using this method during the study and at least 30 days after the end of the study Patient should be willing and able to comply with the study restrictions and attend the visits indicated in the protocol to carry out the follow-up evaluations detailed in the protocol  Diagnosis of asthma-COPD (Chronic Obstructive Pulmonary Disease) overlap syndrome Active and former smokers of>10 packages / year Exacerbations during the previous 4 weeks Current treatment with omalizumab or last dose of omalizumab in the 5 months prior to of the patient in the study. 5 Exposure to another monoclonal antibody Participation in another clinical trial Uncontrolled clinically significant disease, which may interfere with study procedures, interpretation of efficacy results, or compromise patient safety Underlying lung disorder Known hypereosinophilic syndrome A pregnant or lactating woman, or who intends to become pregnant during the study
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Asthma Acute Male or female 2. Aged 18 or above 3. Able to provide informed consent 4. A confirmed asthma diagnosis requiring treatment with inhaled bronchodilator therapy +/ inhaled corticosteroids. 5. Non-smoker (or ex-smoker of 6 months or more with a less than 10 pack year history). 6. Current exacerbation or exacerbation within the previous 12 months. 7. Within 24 hours of having presented to acute secondary care (applicable to current exacerbation only)  Major chronic cardiorespiratory disease other than asthma 2. Significant comorbid condition 3. Receiving maintenance oral corticosteroid therapy or other immunosuppressant or immunomodulatory therapy (including biologics) 4. Pregnant 5. Participating in a clinical trial of an investigational medicinal product (CTIMP). 6. Unable to speak English
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Asthma Adult asthmatics (definition of asthma: FEV1 [forced expiratory volume in 1 second] reversibility of at least 12% and 200 mL after 400 mcg of salbutamol and/or PC20M [provocative concentration of methacholine causing a 20% fall in FEV1]<16 mg/mL) unchanged or increased dose of inhaled corticosteroids prescribed by the pneumologist at the visit FENO (fractional exhaled nitric oxide) > or = 25 ppb  Treatment with oral corticosteroids to treat an asthma exacerbation within 4 weeks before the visit with the pneumologist during the study Change of the dose of ICS (inhaled corticosteroids) during the follow-up of 3 months after the pharmacist's intervention Severe asthma exacerbation requiring oral corticosteroids within the 4 weeks before the follow-up visit (3 months after the pharmacist's intervention)
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Bariatric Surgery Candidate Representative must be member of scientific community of his/her country for bariatric surgery All data of 2015 must be available for each country  None
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Asthma Cough Cough Variant Asthma Individuals aged 18-65 years of age with CVA and individuals with methacholine-induced cough but normal airway sensitivity. The following definitions will be used: 1. CVA: chronic cough (≥8 weeks) is the sole or predominant symptom and positive methacholine challenge (PC20 ≤ 16 mg/mL) and history of cough responding to specific asthma treatment (such as inhaled steroid or 1 week trial of bronchodilator); 2. Methacholine-induced cough but normal airway sensitivity: chronic cough (≥8 weeks) is the sole or predominant symptom and negative methacholine challenges (PC20 > 16 mg/mL) Individuals aged 18-65 years of age with no history of asthma or chronic cough  an exacerbation necessitating a change in medication, emergency department visit or hospitalizations within the previous 4 weeks inability to perform acceptable spirometry medical contraindications to methacholine challenge testing smoking history in excess of 10 pack years Note: Previous treatment with inhaled or systemic corticosteroids is not an criterion; medication use will be recorded and examined in the analysis
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Inhalation Pneumonia Risk Factor In intensive care: Any intubated patient who presented It is a coma with GCS ≤ 12 without VAS protection, whatever the duration Either a proven inhalation, defined by the presence in the VAS of gastric fluid or food Either a suspected inhalation, defined by the extrahospital anamnesis In medicine  Any wrong way (defined by a reflex cough when taking food) Coma without intubation, regardless of duration or depth  Patients with VAP
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Severe Sepsis Adult patients with severe sepsis or septic shock diagnosed less than 24 hours (defined as D0) and hospitalized in the medical resuscitation department of the Amiens-Picardie University Hospital The definitions of severe sepsis and septic shock are the result of the consensus of the Société de Réanimation de Langue Française dating from 2005 Sepsis refers to a systemic inflammatory response syndrome (SIRS) in the presence of suspected or identified infection. Sepsis is said to be severe when lactate> 4 mmol / L or arterial hypotension prior to filling or organ dysfunction is present (one is sufficient): hypoxemia with a PaO2 / FIO2 <300 ratio, renal failure with Hepatic insufficiency with INR> 4 or bilirubin> 78 μmol / l, thrombocytopenia (platelets <100 000 / mm3) and hepatic insufficiency> 176 μmol / l, coagulation disorders with INR> 1.5 Disorders of higher functions with a Glasgow Coma Score <13 Finally, septic shock is defined as a severe sepsis condition with persistent hypotension despite a well-conducted vascular filling (20-40 ml / kg isotonic saline)  Patient with active neoplasia, immune deficiency, autoimmune disease or autoimmune disease Patient under tutorship or curatorship Taking an immunomodulatory or immunosuppressive treatment at the time of the study or the year prior to hospitalization for sepsis Antecedent or haematopoietic graft in progress Pregnancy in progress Known history of infection with human immunodeficiency virus (HIV) type 1 or 2 or with hepatitis B or C virus Patient with agranulocytosis (defined as neutrophils <0.5 G / L)
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 2.0-18.0,  Reactive Airway Disease Wheezing All children having chest wheezes, aged from two years to eighteen years, attending emergency unit of Assiut University Pediatric Hospital, during the period 1⁄6∕2017 to 1∕6⁄2018. They will be examined in Otolaryngology Department, Assiut University Hospital  Refusal of endoscopic nasal examination by care givers.and patients with definite diagnosis of wheeze (bronchiolitis,pneumonia)
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 1.5-17.0,  Asthma Children admitted during the study period with a diagnosis of asthma exacerbation, 2. Children aged 18 months to 17 years of age 3. Children who received oral Corticosteroids in the Emergency Department prior to admission under our hospital Emergency Department Nursing Medical Directive and/or Pre-Printed Order Form  Children who received IV Corticosteroid (CS) in the Emergency Department (ED) 2. Children who received oral CS in the ED prescribed in any other way than through the Children's Hospital of Eastern Ontario ED Nursing Medical Directive and/or Pre-Printed Order Form as doses may not be standardized 3. Children who have received more than one dose of oral CS prior to enrolment 4. Children who have received their first dose of oral CS greater than 12 hours prior to enrolment 5. Children who received oral or IV CS in the previous 4 weeks 6. Children with any of the following: unrepaired congenital heart disease, chronic lung diseases other than asthma, severe neurological impairment and other significant co-morbid disorders as they are not typically treated on our hospital's asthma pathway 7. Children whose caregivers do not understand English or French
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 8.0-20.0,  Asthma in Children Physician-diagnosed asthma BDR ≥8%99 or (if BDR<8%) increased airway responsiveness to methacholine (PD20 <16.81 umol) Four Puerto Rican grandparents Steroid naïve (no treatment with ICS, nasal, or oral corticosteroids in the prior 4 weeks) Parental consent and child's assent to participate in the study  Chronic disease (i.e. respiratory, liver, cardiac, renal, neurologic) other than asthma Severe asthma, as evidenced by: a) intubation for asthma at any time, or b) ≥3 hospitalizations or ≥6 visits to the emergency department/urgent care in the previous year, or c) chronic/continuous need for medications other than single controller therapy [ICS or leukotriene inhibitors] and short-acting β2-agonists Current smoking or former smoking if ≥5 pack-years Inability to perform acceptable spirometry FEV1 <60% of predicted
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 18.0-99.0,  Asthma Moderate to severe asthma requiring medium to high dose inhaled corticosteroids 1. Patients will be recruited through the UAB Asthma Clinic and using the UAB Asthma Clinic Database for the Biospecimen Repository 2. Patients must show spirometry with positive bronchodilator reversibility or have a positive Methacholine Challenge Test within 3 years of enrollment 2. Obesity as defined as BMI over 30 3. Self-reported or radiographic evidence of gastroesophageal reflux disease 4. Ability and willingness to provide informed consent  Inability of the subject to provide informed consent 2. Inability of the subject to undergo bronchoscopy 3. Use of monoclonal antibody within three months prior to enrollment 4. Use of immunosuppressive medication 5. Use of oral corticosteroids or antibiotics 4 weeks prior to enrollment 6. Use of anticoagulants (warfarin/Coumadin and heparin products). 7. Use of aspirin and/or other non-steroidal anti-inflammatory drugs or clopidogrel (Plavix) within 5 days of bronchoscopy. 8. Pregnancy 9. Diagnosis of HIV, active cancer, or liver disease
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 15.0-999.0,  Acute Closed Fracture of Proximal Fifth Metatarsal (Zone II) Criteria:acute closed fracture of proximal fifth metatarsal (zone II) with following 1. History of trauma and pain at lateral side of foot 2. Tenderness at base of 5th metatarsal 3. Radiographic finding shown fracture line at proximal 5th metatarsal bone  more than 1 week 2. comminuted or multiple fracture 3. Open fracture 4. Ligament and tendon injury 5. Previous injury complication: nonunion, delayed union 6. Malignancy 7. refuse to inform consent